RAI2 and small cell lung carcinoma: As the unbiased drug screening approach has revealed a synthetic sick interaction of RAI2 inactivation with topoisomerase I inhibitors, which are approved for the treatment of colorectal [48], ovarian [49] and small cell lung cancers [50], we envision that determining RAI2 gene expression could potentially be used to improve chemotherapeutic outcomes in these cancers or may itself represent a target structure for a new pharmacological approach.